Early evaluation of ADME properties is critical during hit-to-lead and lead optimisation to guide compound design and prioritisation. In vitro assays and in vivo ADME profiling help identify liabilities related to metabolic stability, permeability, bioavailability, and drug-drug interaction potential, enabling informed optimisation decisions. Generating robust ADME data at this stage reduces downstream risk and supports selection of leads with a credible path towards clinical development.
Resources
6 resourcesResource section of Concept Life Sciences website has assay cards on in vitro ADME assays.
Webinar covers: What is ADMET and why is it critical to drug discovery?
Why is (predicted) human PK and exposure so key to success?
What are the key ADMET challenges?
How to design a fit-for-purpose screening cascade?
How to anticipate/identify ADMET challenges and develop adapted solutions?
Resource area with multiple searchable fact sheets including information on ADME assays.
Explains how integrated DMPK (Drug Metabolism and Pharmacokinetics) screening supports small-molecule lead optimisation. It covers the use of in vitro and in vivo studies to assess developability, identify risks and inform PK/PD study design and evaluation of target engagement.
Presents data and strategies for predicting human therapeutic doses early in drug discovery. It explains how dose prediction can inform development decisions and reduce risk when selecting candidate molecules.
Delivery Partner Network members with expertise relevant to this theme.